Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Observational

Predictors of Religious Orientation Attitudes in Menopausal Women

NCT07797296 · tracked via the Priya Life Science Turkey tracker
Phase
Observational
Started
2026-08-26
Last updated
2026-09-01

Condition(s) studied

MenopauseMenopausal SyndromeSexual Dysfunction

Study summary

This descriptive, cross-sectional study examines whether the severity of menopausal symptoms and attitudes toward sexual myths predict intrinsic religious orientation in menopausal women. Menopause is a multidimensional transition with biological, psychological, social and spiritual aspects, and in societies with a strong cultural and religious fabric women may draw on religious orientation as a coping and meaning-making resource. Participants are healthy women aged 49 to 59 with a diagnosis of menopause and no chronic disease, recruited in Konya, Turkey. Data are collected face to face using a personal information form, the Menopause Rating Scale, the Intrinsic Religious Orientation Scale and the Sexual Myths Scale, and analysed with multiple regression.

Eligibility

Sex
FEMALE
Min age
49 Years
Max age
59 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Woman aged 49 to 59 years * Diagnosis of menopause * No chronic health problem * Volunteers to participate and provides written informed consent Exclusion Criteria: \* Presence of a chronic disease (e.g. cardiac disease, diabetes, hypertension)

Primary outcome measure(s)

  • Intrinsic religious orientation (Intrinsic Religious Orientation Scale) — Single assessment at enrollment (Day 1)
    The Intrinsic Religious Orientation Scale (Hoge, 1972; Turkish standardisation by Karaca, 2001) contains 10 items measuring intrinsic religious motivation. Seven items are positively worded and three are negatively worded and reverse coded. Items are rated on a 5-point Likert format scored from 0 (weakest) to 4 (strongest), giving a total score of 0 to 40, with higher scores indicating stronger intrinsic religious orientation.

Trial sites (1)

FacilityCityRegionStatus
Recruitment site (to be specified), Konya Konya Turkey (Türkiye) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07797296 on ClinicalTrials.gov ↗ ← All trials in Turkey